{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:52:49Z","timestamp":1793170369622,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T00:00:00Z","timestamp":1526601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.smim.2018.05.001","type":"journal-article","created":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T21:48:55Z","timestamp":1527112135000},"page":"14-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":589,"special_numbering":"C","title":["Correlates of adjuvanticity: A review on adjuvants in licensed vaccines"],"prefix":"10.1016","volume":"39","author":[{"given":"Giuseppe","family":"Del Giudice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud M.","family":"Didierlaurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2018.05.001_bib0005","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2017.06.005","article-title":"Old and new adjuvants","volume":"47","author":"McKee","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.smim.2018.05.001_bib0010","unstructured":"Food and Drug Administration, https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM478669.pdf, (2015) (Accessed 7 May 2018)."},{"key":"10.1016\/j.smim.2018.05.001_bib0015","unstructured":"Food and Drug Administration, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, manufactured by ID Biomedical Corporation - Questions and Answers. https:\/\/www.fda.gov\/BiologicsBloodVaccines\/SafetyAvailability\/VaccineSafety\/ucm376465.htm, (2018) (Accessed 7 May 2018)."},{"key":"10.1016\/j.smim.2018.05.001_bib0020","unstructured":"European Medicines Agency, Fendrix, hepatitis B (rDNA) vaccine (adjuvanted, adsorbed). http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000550\/human_med_000788.jsp&mid=WC0b01ac058001d124, (2017) (Accessed 7 May 2018)."},{"key":"10.1016\/j.smim.2018.05.001_bib0025","unstructured":"Food and Drug Administration, Cervarix. https:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm186957.htm, (2018) (Accessed 7 May 2018)."},{"key":"10.1016\/j.smim.2018.05.001_bib0030","unstructured":"European Medicines Agency, Cervarix. summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000721\/WC500024632.pdf, (2012) (Accessed 7 May 2018)."},{"key":"10.1016\/j.smim.2018.05.001_bib0035","unstructured":"Food and Drug Administration, Shingrix. https:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm581491.htm, (2017) (Accessed 7 May 2018)."},{"key":"10.1016\/j.smim.2018.05.001_bib0040","unstructured":"Food and Drug Administration, Heplisav-B. https:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm584752.htm, (2018) (Accessed 7 May 2018)."},{"key":"10.1016\/j.smim.2018.05.001_bib0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/21645515.2016.1225635","article-title":"From discovery to licensure, the adjuvant system story","volume":"13","author":"Gar\u00e7on","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.smim.2018.05.001_bib0050","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.coi.2017.07.010","article-title":"Towards an evidence based approach for the development of adjuvanted vaccines","volume":"47","author":"O\u2019Hagan","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.smim.2018.05.001_bib0055","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.vaccine.2012.11.044","article-title":"Disparate adjuvant properties among three formulations of \u201calum\u201d","volume":"31","author":"Cain","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.05.001_bib0060","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1096\/fj.11-184556","article-title":"Antigen depot is not required for alum adjuvanticity","volume":"26","author":"Hutchison","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.smim.2018.05.001_bib0065","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1126\/science.1135299","article-title":"Adjuvant-enhanced antibody responses occur without Toll-like receptor signaling","volume":"314","author":"Gavin","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.smim.2018.05.001_bib0070","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.vaccine.2007.11.054","article-title":"Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice","volume":"26","author":"Wack","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.05.001_bib0075","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/eji.200838549","article-title":"The NLRP3 inflammasome is critical for aluminium hydroxide-mediated IL-1\u03b2 secretion but dispensable for adjuvant activity","volume":"38","author":"Franchi","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.smim.2018.05.001_bib0080","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/ni.1631","article-title":"Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization","volume":"9","author":"Hornung","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2018.05.001_bib0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/mabs.2.1.10328","article-title":"Canakinumab","volume":"2","author":"Dhimolea","year":"2010","journal-title":"mAbs"},{"key":"10.1016\/j.smim.2018.05.001_bib0090","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1128\/CVI.00175-10","article-title":"Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1\u03b2-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study","volume":"17","author":"Chioato","year":"2010","journal-title":"Clin. Vaccin. Immunol."},{"key":"10.1016\/j.smim.2018.05.001_bib0095","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1073\/pnas.0804699105","article-title":"Molecular and cellular signatures of human vaccine adjuvants","volume":"105","author":"Mosca","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2018.05.001_bib0100","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2018.05.001_bib0105","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2094","article-title":"Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake","volume":"9","author":"Liang","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2018.05.001_bib0110","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.vaccine.2004.09.012","article-title":"Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the cynomolgus monkey","volume":"23","author":"Verdier","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.05.001_bib0115","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/bloodadvances.2017011411","article-title":"Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs","volume":"1","author":"Francica","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.smim.2018.05.001_bib0120","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3389\/fimmu.2017.00943","article-title":"Different adjuvants induce common innate pathways that are associated with enhanced adaptive responses against a model antigen in humans","volume":"8","author":"Burny","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2018.05.001_bib0125","doi-asserted-by":"crossref","first-page":"10369","DOI":"10.1038\/ncomms10369","article-title":"Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination","volume":"7","author":"Fourati","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2018.05.001_bib0130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clim.2016.05.007","article-title":"Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: results from a phase II, randomized, multicenter trial","volume":"169","author":"Leroux-Roels","year":"2016","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.smim.2018.05.001_bib0135","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.05.001_bib0140","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/hv.29532","article-title":"Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination","volume":"10","author":"Naud","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.smim.2018.05.001_bib0145","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.smim.2018.05.001_bib0150","series-title":"Inflenza Vaccines for the Future","first-page":"245","article-title":"Non-recent history of influenza pandemics, vaccines, and adjuvants","author":"Lattanzi","year":"2008"},{"key":"10.1016\/j.smim.2018.05.001_bib0155","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/erv.11.192","article-title":"Development and evaluation of AS03, an adjuvant system containing \u03b1-tocopherol and squalene in an oil-in-water emulsion","volume":"11","author":"Gar\u00e7on","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.smim.2018.05.001_bib0160","series-title":"New Generation Vaccines","first-page":"225","article-title":"MF59 adjuvant emulsion","author":"Podda","year":"2004"},{"key":"10.1016\/j.smim.2018.05.001_bib0165","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3389\/fimmu.2017.01760","article-title":"AS03- and MF59-adjuvanted influenza vaccines in children","volume":"8","author":"Wilkins","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2018.05.001_bib0170","first-page":"151","article-title":"Inactivated and adjuvanted influenza vaccines","volume":"386","author":"Del Giudice","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.smim.2018.05.001_bib0175","doi-asserted-by":"crossref","first-page":"21095","DOI":"10.1073\/pnas.1319784110","article-title":"The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination","volume":"110","author":"Vono","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2018.05.001_bib0180","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant system AS03 containing \u03b1-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.05.001_bib0185","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.vaccine.2010.12.090","article-title":"Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes","volume":"29","author":"Calabro","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.05.001_bib0190","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/jat.3130","article-title":"Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines","volume":"35","author":"Segal","year":"2015","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.smim.2018.05.001_bib0195","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1016\/j.vaccine.2013.05.007","article-title":"The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect","volume":"31","author":"Calabro","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.05.001_bib0200","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.4049\/jimmunol.1402071","article-title":"MF59 mediates its B cell adjuvanticity by promoting T follicular helper cells and thus germinal center responses in adult and early life","volume":"194","author":"Mastelic Gavillet","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2018.05.001_bib0205","doi-asserted-by":"crossref","first-page":"e00553","DOI":"10.1128\/CVI.00553-16","article-title":"Long-term persistence of cell-mediated and humoral responses to A(H1N1)pdm09 influenza virus vaccines and the role of the AS03 adjuvant system in adults during two randomized controlled trials","volume":"24","author":"van der Most","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.smim.2018.05.001_bib0210","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/aje\/kws313","article-title":"Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy","volume":"176","author":"Mannino","year":"2012","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.smim.2018.05.001_bib0215","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/irv.12245","article-title":"Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines","volume":"8","author":"van Essen","year":"2014","journal-title":"Influenza Other Respi. Viruses"},{"key":"10.1016\/j.smim.2018.05.001_bib0220","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.vaccine.2017.02.059","article-title":"Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: a systematic review and meta-analysis","volume":"35","author":"Lansbury","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.05.001_bib0225","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1010331","article-title":"Oil-in-water emulsion adjuvant with influenza vaccine in young children","volume":"365","author":"Vesikari","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2018.05.001_bib0230","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2018.05.001_bib0235","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1073\/pnas.1519690113","article-title":"Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood","volume":"113","author":"Nakaya","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2018.05.001_bib0240","doi-asserted-by":"crossref","first-page":"14330","DOI":"10.1073\/pnas.1311998110","article-title":"Human circulating influenza-CD4+ ICOS1+IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses","volume":"110","author":"Spensieri","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2018.05.001_bib0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157066","article-title":"Early rise of blood T follicular helper cell subsets and baseline immunity as predictors of persisting late functional antibody responses to vaccination in humans","volume":"11","author":"Spensieri","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.smim.2018.05.001_bib0250","doi-asserted-by":"crossref","first-page":"37229","DOI":"10.1038\/srep37229","article-title":"Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination","volume":"6","author":"Galson","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.smim.2018.05.001_bib0255","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1073\/pnas.0813390106","article-title":"Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels","volume":"106","author":"Galli","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2018.05.001_bib0260","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1073\/pnas.0903181106","article-title":"Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine","volume":"106","author":"Galli","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2018.05.001_bib0265","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.vaccine.2009.10.017","article-title":"Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study","volume":"28","author":"Leroux-Roels","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.05.001_bib0270","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1016\/j.vaccine.2010.04.030","article-title":"Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates","volume":"28","author":"Ansaldi","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.05.001_bib0275","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1016\/j.vaccine.2006.01.015","article-title":"An MF59-adjuvanted inactivated influenza vaccine containing A\/Panama\/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A\/Fujian\/2002 than a subunit and a split influenza vaccine","volume":"24","author":"Del Giudice","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.05.001_bib0280","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000624","article-title":"Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus","volume":"2","author":"Khurana","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2018.05.001_bib0285","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002336","article-title":"MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines","volume":"3","author":"Khurana","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2018.05.001_bib0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095496","article-title":"Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization","volume":"9","author":"Khurana","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.smim.2018.05.001_bib0295","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1016\/j.vaccine.2017.04.029","article-title":"A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines","volume":"35","author":"Chada","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.05.001_bib0300","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/nm.4223","article-title":"Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain","volume":"22","author":"Raymond","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2018.05.001_bib0305","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ni.3328","article-title":"Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events","volume":"17","author":"Sobolev","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.smim.2018.05.001_bib0310","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems","volume":"10","author":"Gar\u00e7on","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.smim.2018.05.001_bib0315","doi-asserted-by":"crossref","first-page":"39475","DOI":"10.1038\/srep39475","article-title":"Central role of CD169+ lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS01","volume":"6","author":"Detienne","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.smim.2018.05.001_bib0320","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1074\/jbc.M115.683011","article-title":"Identification of QS-21 as an inflammasome-activating molecular component of saponin adjuvants","volume":"291","author":"Marty-Roix","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.smim.2018.05.001_bib0325","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3389\/fimmu.2016.00663","article-title":"Lysosome-dependent activation of human dendritic cells by the vaccine adjuvant QS-21","volume":"7","author":"Welsby","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2018.05.001_bib0330","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.smim.2018.05.001_bib0335","unstructured":"European Medicines Agency, First malaria vaccine receives positive scientific opinion from EMA. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2015\/07\/news_detail_002376.jsp&mid=WC0b01ac058004d5c1, (2015) (Accessed 7 May 2018)."},{"key":"10.1016\/j.smim.2018.05.001_bib0340","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.vaccine.2007.12.038","article-title":"Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers","volume":"26","author":"Vandepapeli\u00e8re","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.05.001_bib0345","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1073\/pnas.1621489114","article-title":"Systems analysis of protective immune responses to RTS,S malaria vaccination in humans","volume":"114","author":"Kazmin","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.smim.2018.05.001_bib0350","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3389\/fimmu.2017.00557","article-title":"Predicting RTS, S vaccine-mediated protection from transcriptomes in a malaria-challenge clinical trial","volume":"8","author":"van den Berg","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2018.05.001_bib0355","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","article-title":"Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells","volume":"193","author":"Didierlaurent","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2018.05.001_bib0360","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN\u03b3 response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"npj Vaccines"},{"key":"10.1016\/j.smim.2018.05.001_bib0365","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.05.001_bib0370","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/600120","article-title":"S.V.E.G. RTS, randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection","volume":"200","author":"Kester","year":"2009","journal-title":"J. Infect. Dis."},{"issue":"11","key":"10.1016\/j.smim.2018.05.001_bib0375","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2018.05.001_bib0380","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2018.05.001_bib0385","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2018.05.001_bib0390","first-page":"117","article-title":"Systems biology of vaccination in the elderly","volume":"363","author":"Duraisingham","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.smim.2018.05.001_bib0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41514-017-0020-0","article-title":"Fighting against a protean enemy: immunosenescence, vaccines, and healthy aging","volume":"4","author":"Del Giudice","year":"2018","journal-title":"npj Aging Mech. Dis."},{"key":"10.1016\/j.smim.2018.05.001_bib0400","doi-asserted-by":"crossref","first-page":"982","DOI":"10.3389\/fimmu.2017.00982","article-title":"Immunobiography and the heterogeneity of immune responses in the elderly: a focus on inflammaging and trained immunity","volume":"8","author":"Franceschi","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2018.05.001_bib0405","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nm.4110","article-title":"Protection against malaria at 1 year and immune correlates following PfSPZ vaccination","volume":"22","author":"Ishizuka","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2018.05.001_bib0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167488","article-title":"Cell-based systems biology analysis of human AS03-adjuvanted H5N1 avian influenza vaccine responses: a phase I randomized controlled trial","volume":"12","author":"Howard","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.smim.2018.05.001_bib0415","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/eji.201242563","article-title":"Impact of preexisting memory to seasonal A\/H1N1 influenza virus on the immune response following vaccination against avian A\/H5N1 virus","volume":"43","author":"Buricchi","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.smim.2018.05.001_bib0420","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin. Vaccine Immunol."}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532318300514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532318300514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T18:23:21Z","timestamp":1545935001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532318300514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":84,"alternative-id":["S1044532318300514"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2018.05.001","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlates of adjuvanticity: A review on adjuvants in licensed vaccines","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2018.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}